Long-term follow-up of mutation carriers will help to establish a dynamic biomarker model for MAPT- or tauopathy-related FTLD, including CBF changes, tau accumulation, neuroinflammation, neurodegeneration and cognitive and linguistic impairments. This evidence concerns the gene MAPT and tauopathy.